Web Analytics Made Easy - StatCounter
Category

Brain Disorders

Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials.

By | Brain Disorders, Epilepsy, Nervous System Diseases, Neurologic Manifestations

Authors: Serena Silvestro, Santa Mammana, Eugenio Cavalli, Placido Bramanti, Emanuela Mazzon
Molecules, April 2019

Cannabidiol (CBD) is one of the cannabinoids with non-psychotropic action, extracted from Cannabis sativa. CBD is a terpenophenol and it has received a great scientific interest thanks to its medical applications. This compound showed efficacy as anti-seizure, antipsychotic, n…

Read More

Cannabis use predicts risks of heart failure and cerebrovascular accidents: results from the National Inpatient Sample.

By | Brain Disorders, Cardiovascular Diseases, Medical Cannabis, Nervous System Diseases

Authors: Aditi Kalla, Parasuram Krishnamoorthy, Akshaya Gopalakrishnan, Vincent Figueredo
Journal of Cardiovascular Medicine, September 2018

BACKGROUND: Cannabis for medicinal and/or recreational purposes has been decriminalized in 28 states as of the 2016 election. In the remaining states, cannabis remains the most commonly used illicit drug. Cardiovascular effects of cannabis use are not well established due to a…

Read More

Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence.

By | Brain Disorders, Epilepsy, Medical Cannabis, Nervous System Diseases

Authors: Emily Stockings, Dino Zagic, Gabrielle Campbell, Megan Weier, Wayne D Hall, et al
Journal of Neurology, Neurosurgery & Psychiatry, July 2018

Review evidence for cannabinoids as adjunctive treatments for treatment-resistant epilepsy. Systematic search of Medline, Embase and PsycINFO was conducted in October 2017. Outcomes were: 50%+ seizure reduction, complete seizure freedom; improved quality of life (QoL). Tolerab…

Read More

Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center.

By | Brain Disorders, Epilepsy, Nervous System Diseases, Neurologic Manifestations

Authors: Giulia S. Porcaria, Cary Fub, Emily D. Doll, Emma G. Carter, Robert P. Carson
Epilepsy & Behavior, March 2018

Medically refractory epilepsy continues to be a challenge worldwide, and despite an increasing number of medical therapies, approximately 1 in 3 patients continues to have seizures. Cannabidiol (CBD), one of many constituents of the Cannabis sativa or marijuana plant, has rece…

Read More

Cannabinoids in treatment-resistant epilepsy: A review.

By | Brain Disorders, Epilepsy, Medical Cannabis, Nervous System Diseases

Authors: Brooke K. O’Connell, David Gloss, Orrin Devinsky
Epilepsy & Behavior, May 2017

Treatment-resistant epilepsy (TRE) affects 30% of epilepsy patients and is associated with severe morbidity and increased mortality. Cannabis-based therapies have been used to treat epilepsy for millennia, but only in the last few years have we begun to collect data from adequ…

Read More

Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex.

By | Brain Disorders, Epilepsy, Nervous System Diseases

Authors: Evan J. Hess, Kirsten A. Moody, Alexandra L. Geffrey, Sarah F. Pollack, et al
Epilepsia, October 2016

OBJECTIVE: Tuberous sclerosis complex (TSC) is an autosomal-dominant genetic disorder with highly variable expression. The most common neurologic manifestation of TSC is epilepsy, which affects approximately 85% of patients, 63% of whom develop treatment-resistant epilepsy. He…

Read More

Δ9-THC Intoxication by Cannabidiol-Enriched Cannabis Extract in Two Children with Refractory Epilepsy: Full Remission after Switching to Purified Cannabidiol.

By | Brain Disorders, Epilepsy, Nervous System Diseases

Authors: José A. S. Crippa, Ana C. S. Crippa, Jaime E. C. Hallak, Rocio Martín-Santos, Antonio W. Zuardi
Frontiers in Pharmacology, 30 September 2016

Animal studies and preliminary clinical trials have shown that cannabidiol (CBD)-enriched extracts may have beneficial effects for children with treatment-resistant epilepsy. However, these compounds are not yet registered as medicines by regulatory agencies. We describe the c…

Read More

Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes.

By | Anorexia, Behavioral Health, Brain Disorders, Clinical Endocannabinoid Deficiency, Digestive System Diseases, Headache Disorders, Immune System Diseases , Irritable Bowel Syndrome, Multiple Sclerosis, Nervous System Diseases, Parkinsonian Disorders, Stress Disorders - Post-Traumatic

Authors: Ethan B. Russo
Cannabis and Cannabinoid Research, 1 July 2016

Medicine continues to struggle in its approaches to numerous common subjective pain syndromes that lack objective signs and remain treatment resistant. Foremost among these are migraine, fibromyalgia, and irritable bowel syndrome, disorders that may overlap in their affected p…

Read More

Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.

By | Brain Disorders, Epilepsy, Nervous System Diseases, Neurologic Manifestations

Authors: Orrin Devinsky, Eric Marsh, Daniel Friedman, Elizabeth Thiele, Linda Laux, et al
The Lancet Neurology, March 2016

BACKGROUND: Almost a third of patients with epilepsy have a treatment-resistant form, which is associated with severe morbidity and increased mortality. Cannabis-based treatments for epilepsy have generated much interest, but scientific data are scarce. We aimed to establish w…

Read More

Cannabinoids and Epilepsy.

By | Epilepsy

Authors: Evan C. Rosenberg, Richard W. Tsien, Benjamin J. Whalley, Orrin Devinsky
Neurotherapeutics, October 2015

Cannabis has been used for centuries to treat seizures. Recent anecdotal reports, accumulating animal model data, and mechanistic insights have raised interest in cannabis-based antiepileptic therapies. In this study, we review current understanding of the endocannabinoid syst…

Read More